IMNN:NASDAQImunon, Inc. analysis
Data as of Sep 26, 2026 - not real-time
- Latest price
- $1.41
- Risk: high
- 9/10High risk
Summary
The moving-average structure behind Imunon, Inc. is bearish at $1.41, with short-term averages lagging the long-term ones. Across the trailing 30 sessions it lost 10.8%. With RSI at 42.1 the momentum picture is neutral, alongside a bearish MACD signal. Watch $1.30 as support and $1.75 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 1105.7% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 51.3%, a beta of 0.60 and a maximum drawdown of 75.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 4 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 1105.7% above where the shares trade now.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 51.3%, a beta of 0.60 and a maximum drawdown of 75.2%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: sell, at a conviction of 4 out of 10.
Top market events
- Nasdaq17dIMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical...
- 1monIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001Leading...
- ADVFN1monIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001IMUNON,...
Market outlook
Short term
< 1 yearCautious
Model confidence5/105 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.57
- MACD momentum is negative
Medium term
1–3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 2.57
- Analyst targets imply +1105.7% versus the current price
Long term
> 3 yearsCautious
Model confidence4/104 out of 10
Key factors
- Analyst targets imply +1105.7% versus the current price
- Negative return on equity of -429.7%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-0.8
ROE-429.72%
ROA-77.99%
Debt/Equity187.29
P/B Ratio3.4
Op. Cash Flow$-15108816
Free Cash Flow$-9529312
Industry P/E30.5
Technical analysis
TrendBearish
RSI42.1
Support$1.30
Resistance$1.75
MA 20$1.48
MA 50$1.56
MA 200$2.57
MACDBearish
VolumeDecreasing
Fear & Greed Index94.88
Valuation
Target Price$17.00
Upside/Downside1105.67%
GradeFair
TypeBlend
Risk assessment
Beta0.60
Volatility51.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.